<- Go Home
Spur Therapeutics Limited
Spur Therapeutics Limited, a clinical-stage biotechnology company, develops transformative adeno-associated virus (AAV) vector-mediated gene therapies. It develops FLT180a for the treatment of hemophilia B.; FLT201 for the treatment of Type 1 Gaucher disease; and FLT190 for the treatment of Fabry disease. in addition, it has research programs for systemic gene therapy. The company was formerly known as Freeline Therapeutics Holdings plc and changed its name to Spur Therapeutics Limited in 2024. The company was founded in 2015 and is headquartered in Stevenage, the United Kingdom.
Market Cap
$28.3M
Volume
181.4K
Cash and Equivalents
$24.2M
EBITDA
-$63.7M
Tax Rate Collected
N/A
Tax Rate Ratio
N/A
Gross Profit
$622.0K
Profit Margin
100.00%
52 Week High
$8.74
52 Week Low
$2.11
Dividend
N/A
Price / Book Value
1.26
Price / Earnings
-0.70
Price / Tangible Book Value
1.47
Enterprise Value
$11.0M
Enterprise Value / EBITDA
-0.17
Operating Income
-$65.4M
Return on Equity
102.35%
Return on Assets
-66.50
Cash and Short Term Investments
$24.2M
Debt
$7.0M
Equity
$22.6M
Revenue
$622.0K
Unlevered FCF
-$38.2M
Sector
Biotechnology
Category
N/A